Related Experiment Video

Updated: Dec 15, 2025

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

12.9K

Abnormal PTBP1 Expression Sustains the Disease Progression of Multiple Myeloma

Hua Bai1, Bing Chen1

  • 1Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China.

Disease Markers
|July 14, 2020
PubMed

Insights

Polypyrimidine tract binding protein (PTBP1) expression correlates with multiple myeloma (MM) progression and poor prognosis. PTBP1 influences alternative splicing of key genes, suggesting it as a potential prognostic marker and therapeutic target for MM.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Multiple myeloma (MM) is a heterogeneous hematopoietic malignancy with variable alternative splicing (AS) profiles.
  • Bioinformatics analysis identified polypyrimidine tract binding protein (PTBP1) as a potential factor in MM progression.

Purpose of the Study:

  • To validate the incidence and prognostic significance of PTBP1 in multiple myeloma patients.
  • To investigate the mechanistic role of PTBP1 in MM progression and therapeutic response.

Main Methods:

  • Analysis of PTBP1 expression across multiple cohorts (n=2971) of newly diagnosed and relapsed MM patients.
  • Correlation analysis of PTBP1 expression with clinicopathological features, cellular proliferation, and treatment response.
  • Exploration of PTBP1's impact on the alternative splicing of aerobic glycolysis-related genes in MM.

Main Results:

  • PTBP1 expression is present at all MM stages and increases with disease progression.
  • Elevated PTBP1 levels are associated with poor prognosis, high tumor burden, and drug resistance.
  • PTBP1 modulates the alternative splicing of PKM2 and other aerobic glycolysis genes, impacting clinical outcomes.

Conclusions:

  • PTBP1 expression is a significant indicator of poor prognosis in multiple myeloma.
  • PTBP1's role in modulating alternative splicing and aerobic glycolysis presents it as a potential therapeutic target for MM.

More Related Videos

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.5K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

522

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.0K